Female infertility. Female infertility of uterine origin
Conditions
Interventions
Intervention group: All the patients receive 8 mg estradiol valterate valerate from the second day of menstrual cycle and continued at least for seven days. HCG (Pregnyl®, Darou Pakhsh, Iran) are admi
Treatment - Drugs
Sponsors
Vice Chancellor for research, Shahid Sadoughi University of Medical Sciences,Yazd, Iran.
Eligibility
Sex/Gender
Female
Age
20 Years to 40 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Infertile women who are candidate for frozen-thawed (ET); with at least 2 previous failed IVF cycle, thin endometrium (thickness less than 7 mm) despite conventional treatment in previous IVF cycles (vaginal estrogen; sildenafil; vitamin E; ...). Exclusion criteria: Oocyte donation; Endometriosis; Polycystic Ovary Syndrome; Intrauterine lesion such as submucosal leiomyoma; history of endometriosis; and thyroid disorders.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical pregnancy. Timepoint: 2-3 weeks after positive pregnancy test. Method of measurement: Fetal heartbeat after 2-3 weeks.;Chemical pregnancy. Timepoint: 2 weeks after emberyo transfer. Method of measurement: serum ßHCG. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Robab Davar
Research and Clinical Centerfor Infertility, Shahid SadoughiUniversity of Medical Sciences,Bouali Av
Outcome results
None listed